Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP synthase. TMC207 exhibits high in vitro activity against mycobacterial strains either susceptible or resistant to all first-line and many second-line drugs, including fluoro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., Koul, A., De Beule, K., Donald, P. R., McNeeley, D. F.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2008
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2493110/
https://ncbi.nlm.nih.gov/pubmed/18505852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01204-07
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares